A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 2	2026-09-09		NCT06561360

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Genentech, Inc.	221
Memorial Sloan Kettering Cancer Center	753

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana Farber Cancer Institute	Boston	United States	133
Mayo Clinic Cancer Center	Rochester	United States	16
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)	Basking Ridge	United States	14
Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	United States	184
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	United States	230
Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)	Commack	United States	4
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	United States	186
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	United States	120
Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison	United States	86
Ohio State University	Columbus	United States	169